%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Schernberg, A.
%A Sagaon Teyssier, Luis
%A Schwarzinger, M.
%A Baillot, S.
%A Bec, M.
%A Benmahammed, L.
%A Even, C.
%A Geoffrois, L.
%A Huguet, F.
%A Le Vu, B.
%A Levy-Bachelot, L.
%A Luchini, S.
%A Pointreau, Y.
%A Robert, C.
%A Temam, S.
%A Epicorl Study Group
%T Clinical and economic burden of head and neck cancer : a nationwide retrospective cohort study from France
%D 2019
%L fdi:010076249
%G ENG
%J Clinicoeconomics and Outcomes Research
%@ 1178-6981
%K head and neck squamous cell carcinoma ; prognosis ; costs ; burden of disease ; National Hospital discharge database
%K FRANCE
%M ISI:000476513600001
%P 441-451
%R 10.2147/ceor.s198312
%U https://www.documentation.ird.fr/hor/fdi:010076249
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers19-08/010076249.pdf
%V 11
%W Horizon (IRD)
%X Objectives: To evaluate the clinical and economic burden of head and neck squamous cell carcinoma (HNSCC) in France. Methods: All 53,255 incident adult patients discharged with a first diagnosis of HNSCC in 2010-2012 were identified from the 2008-2013 French National Hospital Discharge (PMSI) database. We conducted a retrospective longitudinal analysis of prognosis and direct costs attributable to HNSCC. Results: Direct medical costs attributable to HNSCC care amounted to 665 million euros in 2012 in France. The majority (62%) of incident patients were 64 years old or less at HNSCC diagnosis and incurred 1.3-fold higher mean direct costs as compared to elderly patients (41,909 vs 32,221 euros over 3 years, respectively; p<0.001). HNSCC stage at initial treatment was the major driver of mean (SD) direct costs over 3 years (p<0.001): 19,819 (23,150) euros in 31% patients diagnosed at early stage; 46,791 (34,841) euros in 60% patients diagnosed at locally advanced stage; and 43,377 (33,953) euros in 9% patients diagnosed with distant metastasis. About half patients died over 3 years at a median (IQR) age of 63 (56-75) years resulting in 10.9 years-of-life lost on average per incident patient. Conclusion: The present study suggests that the clinical and economic burden of HNSCC is substantial in France.
%$ 056